Tags

Type your tag names separated by a space and hit enter

Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients.
Clin Nephrol 2001; 55(4):313-7CN

Abstract

Plasma homocysteine (tHcy) is an important risk factor for atherosclerosis in dialysis patients. Few data were reported on the prevalence and severity of hyperhomocysteinemia in peritoneal dialysis (PD) patients. In addition, little attention was paid to the search of factors possibly involved in the pathogenesis of hyperhomocysteinemia in these patients. A cross-sectional study was performed in 107 stable PD patients. None of them was given folate or vitamin B12 supplementation before or during the study. Plasma tHcy, serum vitamin B12, serum and erythrocyte folate were measured by immunoenzymatic methods. Genetic analysis of the methylentetrahydrofolate-reductase thermolabile mutation (tMTHFR) was performed in 61 patients. 97% of patients had tHcy levels higher than normal. tHcy was not different between men and women, patients with or without malnutrition, with or without clinically evident atherosclerotic vasculopathy, with or without anemia. tHcy levels were significantly higher in homozygotes for the tMTHFR mutation than in patients carrying the wild type form. Significant univariate correlation was found between hyperhomocysteinemia and time since the start of dialysis, serum and erythrocyte folate and vitamin B12. The best fitted model equation was log tHcy = 108.53 + 0.1606 (duration of dialysis) -1.1053 (s-F) -0.7980 (age) 0.0215 (vitamin B12). Our results agree with those reported by other authors in hemodialysis patients. Despite the large number of PD patients with normal serum vitamin B12 and folate status, the relation between tHcy and vitamin B12 or folate suggests that the supplementation of these vitamins could be useful irrespective of their serum levels, especially in younger patients or in those treated for a long period of time with peritoneal dialysis.

Authors+Show Affiliations

Divisione di Nefrologia e Dialisi, IRCCS Ospedale Maggiore, Milano, Italy. deveccpd@polic.cliea.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11334318

Citation

De Vecchi, A F., et al. "Homocysteine, Vitamin B12, Serum and Erythrocyte Folate in Peritoneal Dialysis Patients." Clinical Nephrology, vol. 55, no. 4, 2001, pp. 313-7.
De Vecchi AF, Bamonti-Catena F, Finazzi S, et al. Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients. Clin Nephrol. 2001;55(4):313-7.
De Vecchi, A. F., Bamonti-Catena, F., Finazzi, S., Patrosso, C., Taioli, E., Novembrino, C., ... Maiolo, A. T. (2001). Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients. Clinical Nephrology, 55(4), pp. 313-7.
De Vecchi AF, et al. Homocysteine, Vitamin B12, Serum and Erythrocyte Folate in Peritoneal Dialysis Patients. Clin Nephrol. 2001;55(4):313-7. PubMed PMID: 11334318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients. AU - De Vecchi,A F, AU - Bamonti-Catena,F, AU - Finazzi,S, AU - Patrosso,C, AU - Taioli,E, AU - Novembrino,C, AU - Colucci,P, AU - Lando,G, AU - De Franceschi,M, AU - Marocchi,A, AU - Maiolo,A T, PY - 2001/5/4/pubmed PY - 2001/9/8/medline PY - 2001/5/4/entrez SP - 313 EP - 7 JF - Clinical nephrology JO - Clin. Nephrol. VL - 55 IS - 4 N2 - Plasma homocysteine (tHcy) is an important risk factor for atherosclerosis in dialysis patients. Few data were reported on the prevalence and severity of hyperhomocysteinemia in peritoneal dialysis (PD) patients. In addition, little attention was paid to the search of factors possibly involved in the pathogenesis of hyperhomocysteinemia in these patients. A cross-sectional study was performed in 107 stable PD patients. None of them was given folate or vitamin B12 supplementation before or during the study. Plasma tHcy, serum vitamin B12, serum and erythrocyte folate were measured by immunoenzymatic methods. Genetic analysis of the methylentetrahydrofolate-reductase thermolabile mutation (tMTHFR) was performed in 61 patients. 97% of patients had tHcy levels higher than normal. tHcy was not different between men and women, patients with or without malnutrition, with or without clinically evident atherosclerotic vasculopathy, with or without anemia. tHcy levels were significantly higher in homozygotes for the tMTHFR mutation than in patients carrying the wild type form. Significant univariate correlation was found between hyperhomocysteinemia and time since the start of dialysis, serum and erythrocyte folate and vitamin B12. The best fitted model equation was log tHcy = 108.53 + 0.1606 (duration of dialysis) -1.1053 (s-F) -0.7980 (age) 0.0215 (vitamin B12). Our results agree with those reported by other authors in hemodialysis patients. Despite the large number of PD patients with normal serum vitamin B12 and folate status, the relation between tHcy and vitamin B12 or folate suggests that the supplementation of these vitamins could be useful irrespective of their serum levels, especially in younger patients or in those treated for a long period of time with peritoneal dialysis. SN - 0301-0430 UR - https://www.unboundmedicine.com/medline/citation/11334318/Homocysteine_vitamin_B12_serum_and_erythrocyte_folate_in_peritoneal_dialysis_patients_ L2 - https://medlineplus.gov/folicacid.html DB - PRIME DP - Unbound Medicine ER -